About MolWard

What is MolWard?

 

MolWard is a comprehensive, web-based in silico cheminformatics platform designed to accelerate early-stage pharmaceutical development and streamline regulatory compliance. By unifying predictive degradation profiling with a dual-methodology ICH M7 hazard assessment into a single automated workflow, MolWard empowers pharmaceutical scientists to identify chemical liabilities, predict mutagenic risks, and plan analytical methods before ever stepping into the laboratory.

​

The Problem We Solve

 

The modern pharmaceutical landscape is facing unprecedented regulatory scrutiny regarding drug substance stability and mutagenic impurities. Following recent global safety crises involving the "Cohort of Concern" (specifically N-nitrosamines), regulatory agencies such as the FDA and EMA now mandate highly stringent safety thresholds.

Traditionally, identifying these risks required resource-intensive experimental forced degradation studies and costly in vitro Ames testing. These empirical methods frequently create substantial bottlenecks in early drug formulation. MolWard was engineered to eliminate these bottlenecks by providing rapid, highly accurate computational foresight.

​

Our Core Technologies

 

MolWard operates on robust cheminformatics tools, deterministic chemistry rules, and modern machine learning.

​

• Predictive Forced Degradation Engine: MolWard simulates severe stress conditions (extreme pH, oxidative stress, photolysis, and elevated temperatures) using a proprietary library of over 50 deterministic reaction rules. It generates theoretical degradant structures and automatically calculates critical analytical parameters, including theoretical EI-MS fragmentation, UV-Vis spectra, and pKa profiles.

​

• Dual-Methodology ICH M7(R2) Assessment: To satisfy strict regulatory mandates, MolWard executes a two-pronged safety evaluation:

  • Expert Rule-Based System: Identifies established toxicophores using Ashby-Tennant alerts and Benigni-Bossa rules.

  • Statistical QSAR Modeling: A Random Forest machine learning classifier—trained on a curated dataset of over 6,700 compounds from the Hansen Mutagenicity and ECVAM databases—predicts Ames mutagenicity independently of structural alerts.

​

• Dynamic Nitrosamine CPCA Scoring: For identified nitrosamine risks, MolWard automatically executes the Carcinogenic Potency Categorization Approach (CPCA). By computationally parsing the steric environment and alpha-hydrogen count of the pharmacophore, the system assigns the exact FDA/EMA Acceptable Intake (AI) limit (ranging from 18 to 1500 ng/day).

​

• Structural Read-Across & Pharmacopeia Integration: MolWard bridges the gap between software and the physical lab. Mutagenic predictions are backed by literature references from our known-toxin database. Furthermore, theoretical degradants are automatically cross-referenced against the United States Pharmacopeia (USP) and European Pharmacopoeia (EP) databases, providing analytical chemists with direct catalog numbers for reference standards.

• ​

Scientific Validation

 

MolWard is built on rigorous, transparent science. Our Statistical QSAR model has been strictly validated against unseen test sets, achieving a 77.71% Accuracy and an exceptional ROC-AUC score of 0.869, ensuring a high degree of confidence and a low rate of false positives.

​

Who Uses MolWard?

 

MolWard is designed as a daily-use utility for cross-functional pharmaceutical teams:

• Analytical Chemists: For anticipating chromatographic peaks and sourcing USP/EP reference standards during stability-indicating method (SIM) development.

• Formulation Scientists: For selecting optimal packaging and excipients by understanding intrinsic API vulnerabilities to heat, light, and moisture.

• Regulatory Toxicologists: For generating rapid, defensible, dual-methodology risk assessments for regulatory submissions.

• Process Chemists: For identifying synthesis route risks, particularly concerning nitrosating agents and amine precursors.